Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
235 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (19)
  • (-) Currently Recruiting (7)
  • Closed (12)

Medical Condition

  • Show all (235)
  • Addiction (3)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (3)
  • Bone & Muscle (2)
  • Cancer (10)
  • COVID-19 (Coronavirus) (8)
  • Diabetes (7)
  • Ear, Nose and Throat (7)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (45)
  • Heart Disease (17)
  • Infectious Disease (11)
  • Insomnia (1)
  • Liver Disease (17)
    • (-) Cirrhosis of the Liver (3)
    • Liver Failure (1)
    • MASH (formerly NASH) (1)
  • Lung Disease (2)
  • Neurological Disorders (30)
  • Nutrition (2)
  • Obesity (8)
  • Obstetrics & Gynecology (10)
  • Pediatrics (15)
  • Psychiatric Disorders (9)
  • Rehabilitation (2)
  • Stroke (2)
  • Transplant (16)
    • (-) Kidney Transplant (4)
    • Liver Transplant (10)
  • Vascular Conditions (1)
Displaying 1 - 7 of 7

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor: The IMPROVE Trial

Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether giving an investigational drug called C1 esterase inhibitor (C1INH) directly into the donor kidney before transplant can improve kidney function one year after surgery. At the time of the deceased donor kidney transplant, participants will be randomly assigned to received a kidney that has been treated with either C1INH or a…
Read More

MODERNIZE: A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Currently Recruiting
The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG…
Read More

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults with Child Pugh A and B Cirrhosis

Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Giuseppe Cullaro, MD
Status: Currently Recruiting
Researchers at Columbia University Irving Medical Center are investigating whether PHIN-24 is safe and tolerable after single and multiple ascending doses for people with advanced cirrhosis. Advanced liver cirrhosis is the late stage of chronic liver scarring, where the liver has lost most of its ability to function normally. Study participants will: 1) Be…
Read More

Study to Test if BI 3802876 is Tolerated in People W/ Compensated Liver Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Julia Wattacheril, MD, MPH
Status: Currently Recruiting
The purpose of this research study is to determine how well BI3802876 is tolerated in people living with cirrhosis due to a liver condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The study medication, BI3802876, is investigational, meaning it has not yet been approved by the United States Food and Drug…
Read More

A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation

Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether a new investigational medicine called frexalimab can safely and effectively prevent kidney transplant rejection compared to tacrolimus, a standard medication currently used after transplant. Participants will be randomly assigned to receive either frexalimab (given by injection every 4 weeks) or tacrolimus (taken as capsules…
Read More

VEL-101 (VELOXIS) to Prevent Rejection After Kidney Transplantation

Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-transplant to prevent rejection. Participants will be…
Read More

Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU)

Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
The purpose of this research study is to determine whether rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives. The study drug, rosuvastatin, is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA). Participants will…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science